Clinical Trial: Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906341) titled 'Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer' on April 01.

Brief Summary: This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Fallopian Tube Cancer Peritoneal Neoplasms

Intervention: DRUG: Relacorilant 150 mg once daily (QD)

Relacorilant is administered as capsules for oral dosing on the day before, t...